We will try to advance the onset time of N1437D animals by implementing a comparable treatment strategy involving environmental pollutants in our future study, to establish a closer resemblance between this model organism and the actual clinical scenario of patients and better serve the development of treatments for LRRK2-related disease
Last medically reviewed: 2026-04-27 by GLP3 Planner editorial
Kiss T, Nyul-Toth A, Balasubramanian P, Tarantini S, Ahire C, DelFavero J, Yabluchanskiy A, Csipo T, Farkas E, Wiley G, Garman L, Csiszar A, Ungvari Z
Most patients find that the process of self-administration is much simpler than they anticipated
Retatrutide is expected to be a once-weekly subcutaneous injection, similar to other GLP-1 medications
Blood Pressure and Heart Rate Some patients on GLP-1 therapy experience changes in blood pressure or a slight increase in resting heart rate